Guinea-Bissau Cancels US-Funded Hepatitis B Vaccine Study Amidst Health Concerns and Sovereignty Row
In a move that has raised eyebrows in the international health community, Guinea-Bissau has suspended a controversial US-funded study on hepatitis B vaccines, citing concerns over ethics. The decision comes amidst growing tensions between the West African nation and foreign donors over issues of sovereignty and research ethics.
The study, which aimed to compare the effects of giving infants hepatitis B vaccines at birth versus six weeks of age, had been at the center of a heated debate over its design and ethics. Critics argued that withholding vaccines from some newborns could put them at risk of severe illness and death. The World Health Organization recommends administering the vaccine within 24 hours of birth.
Guinea-Bissau's Minister of Health, Quinhin Nantote, confirmed that the trial had been cancelled due to concerns over scientific review, stating that "the science was not well-reviewed." A team of experts from the Africa Centres for Disease Control and Prevention (Africa CDC) will now travel to Guinea-Bissau to help officials review the study.
The decision has sparked controversy, with some accusing the US Department of Health and Human Services (HHS) of attempting to undermine the credibility of the Africa CDC. HHS officials have questioned the organization's ability to conduct research ethically, labeling it a "powerless, fake organization." However, others have come to the defense of the Africa CDC, highlighting its key role in responding to outbreaks with global implications.
"This is not acceptable," said Abdulhammad Babatunde, a medical doctor and global health researcher. "To prevent things like the Tuskegee study and others, the control group has to get the standard of care, and the intervention group should get [potentially] better care." The researcher expressed concerns that infants would be used as "lab rats" for the vaccine trial.
The controversy raises questions about the balance of power in international health research. Guinea-Bissau's decision highlights the need for countries to maintain control over their own research agendas, free from external interference.
"This is the sovereignty of the country," said Jean Kaseya, director-general of the Africa CDC. "I don't know what will be this decision, but I will support the decision that the minister will make." The statement underscores the importance of respecting countries' right to decide their own research priorities.
The cancellation of the study has sparked a heated debate about ethics in international health research. While some have praised Guinea-Bissau's decision, others have criticized it as a setback for global efforts to combat infectious diseases.
In a move that has raised eyebrows in the international health community, Guinea-Bissau has suspended a controversial US-funded study on hepatitis B vaccines, citing concerns over ethics. The decision comes amidst growing tensions between the West African nation and foreign donors over issues of sovereignty and research ethics.
The study, which aimed to compare the effects of giving infants hepatitis B vaccines at birth versus six weeks of age, had been at the center of a heated debate over its design and ethics. Critics argued that withholding vaccines from some newborns could put them at risk of severe illness and death. The World Health Organization recommends administering the vaccine within 24 hours of birth.
Guinea-Bissau's Minister of Health, Quinhin Nantote, confirmed that the trial had been cancelled due to concerns over scientific review, stating that "the science was not well-reviewed." A team of experts from the Africa Centres for Disease Control and Prevention (Africa CDC) will now travel to Guinea-Bissau to help officials review the study.
The decision has sparked controversy, with some accusing the US Department of Health and Human Services (HHS) of attempting to undermine the credibility of the Africa CDC. HHS officials have questioned the organization's ability to conduct research ethically, labeling it a "powerless, fake organization." However, others have come to the defense of the Africa CDC, highlighting its key role in responding to outbreaks with global implications.
"This is not acceptable," said Abdulhammad Babatunde, a medical doctor and global health researcher. "To prevent things like the Tuskegee study and others, the control group has to get the standard of care, and the intervention group should get [potentially] better care." The researcher expressed concerns that infants would be used as "lab rats" for the vaccine trial.
The controversy raises questions about the balance of power in international health research. Guinea-Bissau's decision highlights the need for countries to maintain control over their own research agendas, free from external interference.
"This is the sovereignty of the country," said Jean Kaseya, director-general of the Africa CDC. "I don't know what will be this decision, but I will support the decision that the minister will make." The statement underscores the importance of respecting countries' right to decide their own research priorities.
The cancellation of the study has sparked a heated debate about ethics in international health research. While some have praised Guinea-Bissau's decision, others have criticized it as a setback for global efforts to combat infectious diseases.